Medicines and Allied Substances [No. of 2013 29 (b) that the advertisement was received in the ordinary course of business and the person charged had no reason to suspect that its publication would amount to an offence under this Act; and (c) that the advertisement was commissioned by a third party. 46. (1) The Authority may, where it determines that it is not in the public interest that any medicine or allied substance should be made available to the public, by notice, in writing, served on any person or in the Gazette, direct that person to return the medicine or allied substance which the person has in that person’s possession to— Recall of medicine, etc. from circulation (a) the manufacturer of the medicine or allied substance; (b) in the case of any imported medicine or allied substance, to the importer concerned; (c) deliver it or send it to the Authority or such other person as the Authority may designate. (2) The Authority may, by notice, in writing, direct the manufacturer or importer of the medicine or allied substance referred to in subsection (1) or the person referred to in paragraph (c) of subsection (1), who has in their possession any quantity of the medicine or allied substance, including the returned quantity to deal with or dispose of that quantity in such manner as the Authority may determine. (3) A person shall not sell any medicine or allied substance which is the subject of a notice under subsection (1). (4) A person who contravenes subsection (3) commits an offence and is liable, upon conviction, to a fine not exceeding one million penalty units or to imprisonment for a period not exceeding three years, or to both. 47. The Minister may, on the recommendation of the Authority, by statutory instrument, make regulations for monitoring the safety of medicines and allied substances. 48. (1) The Authority shall keep and maintain a Register of Marketing Authorisations issued under this Act. (2) The Register referred to in subsection (1) shall be kept at the offices of the Authority and shall be open to inspection by the public at such times and on such conditions, including the payment of a fee for inspection as the Board may determine. PART VI REGULATION OF CLINICAL TRIALS Monitoring medicine and allied substance Register of Marketing Authorisations